Pharmacokinetics and pharmacodynamics of propofol microemulsion and lipid emulsion after an intravenous bolus and variable rate infusion
Kye-Min Kim, Byung-Moon Choi, Si-Won Park, Soo-Han Lee, Lane V Christensen, Jiaye Zhou, Byung-Hoon Yoo, Hye-Won Shin, Kyun-Seop Bae, Steven E Kern, Sung-Hong Kang, Gyu-Jeong Noh, Kye-Min Kim, Byung-Moon Choi, Si-Won Park, Soo-Han Lee, Lane V Christensen, Jiaye Zhou, Byung-Hoon Yoo, Hye-Won Shin, Kyun-Seop Bae, Steven E Kern, Sung-Hong Kang, Gyu-Jeong Noh
Abstract
Background: The aim of this trial was to evaluate the induction and recovery characteristics of microemulsion propofol (Aquafol; Daewon Pharmaceutical Co., Ltd., Seoul, Korea). Pharmacokinetics, pharmacodynamics, and safety profile were investigated. Lipid emulsion propofol (Diprivan; AstraZeneca, London, United Kingdom) was used as a comparator.
Methods: Thirty-one healthy volunteers aged 20-79 yr were given an intravenous bolus of propofol 2 mg/kg, followed by variable rate infusion for 60 min. Each volunteer was studied twice with different formulations at an interval of 1 week. Arterial concentrations of propofol were measured, and Bispectral Index was used as a surrogate measure of propofol effect. The induction and recovery characteristics including bioequivalence were evaluated by noncompartmental analysis. The pharmacokinetics and pharmacodynamics were investigated using a population approach with mixed effects modeling. The rate, severity, and causal relation of adverse events were analyzed.
Results: Both formulations were bioequivalent. The observed time to peak effect after a bolus of both formulations was 1.5 min. Plasma concentration of propofol at loss of consciousness, time to loss of consciousness after a bolus, and time to recovery of consciousness after discontinuation of infusion did not show significant differences. The population pharmacokinetics and pharmacodynamics revealed a variety of differences between two formulations. Aquafol showed similar safety profile to Diprivan.
Conclusions: The efficacy and safety of Aquafol were not different from those of Diprivan within the dose range in this study.
Source: PubMed